Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenerx Biopharmaceuticals RGRX

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.

Recent & Breaking News (OTCQB:RGRX)

RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage

PR Newswire February 25, 2015

RegeneRx Updates Website

PR Newswire February 19, 2015

RegeneRx Releases Letter to Shareholders

PR Newswire February 17, 2015

RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S.

PR Newswire January 28, 2015

RegeneRx Partner Submits Phase IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome

PR Newswire December 29, 2014

Researchers Report Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model

PR Newswire November 25, 2014

RegeneRx Announces Management Changes

PR Newswire November 6, 2014

U.S. Patent Office Significantly Extends the Term of Three RegeneRx Patents

PR Newswire November 3, 2014

Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model

PR Newswire October 24, 2014

Dr. Michael Chopp Reports on Successful Remodeling of the Central and Peripheral Nervous Systems after Injury/Disease Using Thymosin Beta 4

PR Newswire October 23, 2014

RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy

PR Newswire October 20, 2014

RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging

PR Newswire September 30, 2014

RegeneRx Receives $1 Million Pursuant to Product License and Stock Purchase Agreement

PR Newswire September 3, 2014

New Report: Thymosin ?4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice

Business Wire July 15, 2014

RegeneRx's Strategic Partner G-treeBNT Preparing for Phase III Dry Eye Trials in Asia with RGN-259

Business Wire July 7, 2014

Chinese FDA Accepts Phase 2 IND for RGN-259 for Dry Eye

Business Wire June 23, 2014

RegeneRx Chairman, Dr. Allan L. Goldstein, to Speak at Major Drug Industry Conference

Business Wire June 10, 2014

RegeneRx Issues Letter to Shareholders

Business Wire May 22, 2014

RegeneRx Receives Notice of Allowance for U.S. Patent for Treatment of Stroke

Business Wire April 21, 2014

RegeneRx Receives $1.35 Million Pursuant to Product License And Stock Purchase Agreement

Business Wire March 28, 2014